Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours

The dose and schedule recommended for further study with SNX-5422 is 100 mg/m2 QOD 3 weeks on/1 week off based on improved tolerability and preliminary evidence of clinical activity.